Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 5/2013

01-05-2013 | Case Based Review

Leflunomide-induced DRESS syndrome with renal involvement and vasculitis

Authors: Benzeeta Pinto, Varun Dhir, Sabari Krishnan, Ritambhra Nada

Published in: Clinical Rheumatology | Issue 5/2013

Login to get access

Abstract

DRESS or drug reaction (or rash) with eosinophilia and systemic symptoms belongs to the severe cutaneous adverse reaction group and is characterized by hematological abnormalities and visceral organ involvement. Although most often related with anticonvulsant and sulfonamide use, it is reported with numerous other drugs. We report an unusual case of DRESS syndrome due to Leflunomide, also complicated by renal involvement in the form of granulomatous interstitial nephritis and vasculitis. On a review of the literature, eight similar cases were found, and these are discussed.
Literature
1.
Bocquet H, Bagot M, Roujeau JC (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15(4):250–257PubMedCrossRef
2.
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L et al (2011) The DRESS syndrome: a literature review. Am J Med 124(7):588–597PubMedCrossRef
3.
Walsh SA, Creamer D (2011) Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 36(1):6–11PubMedCrossRef
4.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M et al (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156(3):609–611PubMedCrossRef
5.
Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59(11):841–849PubMedCrossRef
6.
Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W (1986) Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 105(2):179–184PubMedCrossRef
7.
Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC (1998) Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 139(6):1026–1032PubMedCrossRef
8.
Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int 55(1):1–8PubMedCrossRef
9.
Augusto JF, Sayegh J, Simon A, Croue A, Chennebault JM, Cousin M et al (2009) A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 24(9):2940–2942PubMedCrossRef
10.
Kim MS, Lee JH, Park K, Son SJ (2011) Allopurinol-induced DRESS syndrome with a histologic pattern consistent with interstitial granulomatous drug reaction. Am J Dermatopathol. doi:10.​1097/​DAD.​0b013e3181c0e14d​
11.
Shiohara T, Iijima M, Ikezawa Z, Hashimoto K (2007) The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 156(5):1083–1084PubMedCrossRef
12.
Gros C, Delesalle F, Gautier S, Delaporte E (2008) Leflunomide-induced skin necrosis. Ann Dermatol Venereol 135(3):205–208PubMedCrossRef
13.
Hassikou H, El Haouri M, Tabache F, Baaj M, Safi S, Hadri L (2008) Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine 75(5):597–599PubMedCrossRef
14.
Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK et al (2001) Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60(10):913–923PubMedCrossRef
15.
Holm EA, Balslev E, Jemec GB (2001) Vasculitis occurring during leflunomide therapy. Dermatology 203(3):258–259PubMedCrossRef
16.
Macdonald J, Zhong T, Lazarescu A, Gan BS, Harth M (2004) Vasculitis associated with the use of leflunomide. J Rheumatol 31(10):2076–2078PubMed
17.
Uppal MRR, Srinivas CR (2004) Leflunomide induced drug rash and hepatotoxicity. Indian J Dermatol 49:154–155
18.
Shastri V, Betkerur J, Kushalappa PA, Savita TG, Parthasarathi G (2006) Severe cutaneous adverse drug reaction to leflunomide: a report of five cases. Indian J Dermatol Venereol Leprol 72(4):286–289PubMedCrossRef
19.
Do-Pham G, Charachon A, Duong TA, Thille AW, Benhaiem N, Bagot M et al (2011) Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases. Br J Dermatol 165(1):207–209PubMedCrossRef
20.
Metadata
Title
Leflunomide-induced DRESS syndrome with renal involvement and vasculitis
Authors
Benzeeta Pinto
Varun Dhir
Sabari Krishnan
Ritambhra Nada
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2152-8

Other articles of this Issue 5/2013

Clinical Rheumatology 5/2013 Go to the issue

Case Based Review

Crowned dens syndrome: a rare cause of acute neck pain

Brief Report

Antibodies to citrullinated peptides in tuberculosis

Case Based Review

Antisynthetase antibody syndrome: case report and review of the literature

Original Article

Clinical and serological features of systemic sclerosis in a Chinese cohort

Brief Report

A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers

Original Article

Osteomyelitis complicating scleroderma digital ulcers
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits